191 related articles for article (PubMed ID: 37509089)
1. Improving the Stability and Effectiveness of Immunotropic Squalene Nanoemulsion by Adding Turpentine Oil.
Krasnova OA; Minaychev VV; Akatov VS; Fadeev RS; Senotov AS; Kobyakova MI; Lomovskaya YV; Lomovskiy AI; Zvyagina AI; Krasnov KS; Shatalin YV; Penkov NV; Zhalimov VK; Molchanov MV; Palikova YA; Murashev AN; Maevsky EI; Fadeeva IS
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509089
[TBL] [Abstract][Full Text] [Related]
2. Development of Squalene-Based Oil-in-Water Emulsion Adjuvants Using a Self-Emulsifying Drug Delivery System for Enhanced Antigen-Specific Antibody Titers.
Chae GE; Kim DW; Jin HE
Int J Nanomedicine; 2022; 17():6221-6231. PubMed ID: 36531114
[TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family.
Fox CB; Van Hoeven N; Granger B; Lin S; Guderian JA; Hartwig A; Marlenee N; Bowen RA; Soultanov V; Carter D
Phytomedicine; 2019 Nov; 64():152927. PubMed ID: 31465981
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.
Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
Vaccine; 2011 Nov; 29(51):9563-72. PubMed ID: 21906648
[TBL] [Abstract][Full Text] [Related]
5. Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system.
Chung H; Kim TW; Kwon M; Kwon IC; Jeong SY
J Control Release; 2001 Apr; 71(3):339-50. PubMed ID: 11295226
[TBL] [Abstract][Full Text] [Related]
6. Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.
Iyer V; Cayatte C; Guzman B; Schneider-Ohrum K; Matuszak R; Snell A; Rajani GM; McCarthy MP; Muralidhara B
Hum Vaccin Immunother; 2015; 11(7):1853-64. PubMed ID: 26090563
[TBL] [Abstract][Full Text] [Related]
7. Manufacture of Oil-in-Water Emulsion Adjuvants.
Haensler J
Methods Mol Biol; 2017; 1494():165-180. PubMed ID: 27718193
[TBL] [Abstract][Full Text] [Related]
8. Optimising the oil phases of aluminium hydrogel-stabilised emulsions for stable, safe and efficient vaccine adjuvant.
Yuan L; Gao XD; Xia Y
Front Chem Sci Eng; 2022; 16(6):973-984. PubMed ID: 35070473
[TBL] [Abstract][Full Text] [Related]
9. The effects of serum on the stability and the transfection activity of the cationic lipid emulsion with various oils.
Kim YJ; Kim TW; Chung H; Kwon IC; Sung HC; Jeong SY
Int J Pharm; 2003 Feb; 252(1-2):241-52. PubMed ID: 12550800
[TBL] [Abstract][Full Text] [Related]
10. Antioxidative Protection of Squalene Adjuvant and Rabies Vaccine with Adjuvant.
Ondrejková A; Süli J; Harvanová J; Ondrejka R; Prokeš M
Biol Pharm Bull; 2017 Jul; 40(7):1029-1034. PubMed ID: 28428486
[TBL] [Abstract][Full Text] [Related]
11. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
Deng J; Cai W; Jin F
Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
[TBL] [Abstract][Full Text] [Related]
12. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.
Fox CB; Lin S; Sivananthan SJ; Dutill TS; Forseth KT; Reed SG; Vedvick TS
Pharm Dev Technol; 2011 Oct; 16(5):511-9. PubMed ID: 20550484
[TBL] [Abstract][Full Text] [Related]
13. Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.
Fox CB; Barnes V L; Evers T; Chesko JD; Vedvick TS; Coler RN; Reed SG; Baldwin SL
Influenza Other Respir Viruses; 2013 Sep; 7(5):815-26. PubMed ID: 23122325
[TBL] [Abstract][Full Text] [Related]
14. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.
Klucker MF; Dalençon F; Probeck P; Haensler J
J Pharm Sci; 2012 Dec; 101(12):4490-500. PubMed ID: 22941944
[TBL] [Abstract][Full Text] [Related]
15. Unsaturated Squalene Content in Emulsion Vaccine Adjuvants Plays a Crucial Role in ROS-Mediated Antigen Uptake and Cellular Immunity.
Huang CH; Huang CY; Huang MH
Mol Pharm; 2018 Feb; 15(2):420-429. PubMed ID: 29237267
[TBL] [Abstract][Full Text] [Related]
16. An alternative renewable source of squalene for use in emulsion adjuvants.
Brito LA; Chan M; Baudner B; Gallorini S; Santos G; O'Hagan DT; Singh M
Vaccine; 2011 Aug; 29(37):6262-8. PubMed ID: 21723355
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.
Fox CB; Anderson RC; Dutill TS; Goto Y; Reed SG; Vedvick TS
Colloids Surf B Biointerfaces; 2008 Aug; 65(1):98-105. PubMed ID: 18440205
[TBL] [Abstract][Full Text] [Related]
18. Experimental squalene adjuvant. I. Preparation and testing of its effectiveness.
Süli J; Benísek Z; Eliás D; Svrcek S; Ondrejková A; Ondrejka R; Bajová V
Vaccine; 2004 Sep; 22(25-26):3464-9. PubMed ID: 15308373
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.
Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
AAPS PharmSciTech; 2012 Jun; 13(2):498-506. PubMed ID: 22415641
[TBL] [Abstract][Full Text] [Related]
20. Squalene and squalane emulsions as adjuvants.
Allison AC
Methods; 1999 Sep; 19(1):87-93. PubMed ID: 10525443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
